The Food and Drug Administration today issued Gilead Sciences an emergency use authorization for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.

FDA previously allowed for study of the drug under clinical trials, as well as expanded access use for individual patients and through a multi-patient expanded access program coordinated by Gilead.

The National Institutes of Health this week reported that a clinical trial provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a placebo.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…
Headline
Learn how Loyola University Health System’s pop-up COVID-19 testing laboratory broadened collaboration between clinicians and hospital leadership, improved…
Headline
The Biden Administration plans to continue the COVID-19 public health emergency beyond July 15, administration officials told CNN this week. The…
Headline
U.S. residents can order online eight more free at-home tests for COVID-19, the White House announced yesterday. People who have difficulty accessing the…
Headline
The Food and Drug Administration today authorized a single Pfizer COVID-19 booster dose for children aged 5-11 who completed the Pfizer vaccine primary series…
Headline
A recent op-ed in the online publication STAT contains “blatant factual inaccuracies” and omits critical information about hospital and health systems’…